COLL
Price
$27.36
Change
-$0.78 (-2.77%)
Updated
Apr 7, 04:59 PM (EDT)
Capitalization
1.24B
31 days until earnings call
ESPR
Price
$1.19
Change
-$0.04 (-3.25%)
Updated
Apr 7, 04:59 PM (EDT)
Capitalization
495.94M
36 days until earnings call
Ad is loading...

COLL vs ESPR

Header iconCOLL vs ESPR Comparison
Open Charts COLL vs ESPRBanner chart's image
Collegium Pharmaceutical
Price$27.36
Change-$0.78 (-2.77%)
Volume$9.64K
Capitalization1.24B
Esperion Therapeutics
Price$1.19
Change-$0.04 (-3.25%)
Volume$61.25K
Capitalization495.94M
COLL vs ESPR Comparison Chart
Loading...
COLL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ESPR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
COLL vs. ESPR commentary
Apr 08, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is COLL is a Buy and ESPR is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
Apr 08, 2025
Stock price -- (COLL: $28.14 vs. ESPR: $1.23)
Brand notoriety: COLL and ESPR are both not notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: COLL: 98% vs. ESPR: 134%
Market capitalization -- COLL: $1.24B vs. ESPR: $495.94M
COLL [@Pharmaceuticals: Other] is valued at $1.24B. ESPR’s [@Pharmaceuticals: Other] market capitalization is $495.94M. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $77.48B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $3.67B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

COLL’s FA Score shows that 1 FA rating(s) are green whileESPR’s FA Score has 0 green FA rating(s).

  • COLL’s FA Score: 1 green, 4 red.
  • ESPR’s FA Score: 0 green, 5 red.
According to our system of comparison, COLL is a better buy in the long-term than ESPR.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

COLL’s TA Score shows that 3 TA indicator(s) are bullish while ESPR’s TA Score has 4 bullish TA indicator(s).

  • COLL’s TA Score: 3 bullish, 4 bearish.
  • ESPR’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, ESPR is a better buy in the short-term than COLL.

Price Growth

COLL (@Pharmaceuticals: Other) experienced а -5.28% price change this week, while ESPR (@Pharmaceuticals: Other) price change was -18.00% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -5.79%. For the same industry, the average monthly price growth was -4.20%, and the average quarterly price growth was -12.97%.

Reported Earning Dates

COLL is expected to report earnings on Jul 31, 2025.

ESPR is expected to report earnings on Aug 05, 2025.

Industries' Descriptions

@Pharmaceuticals: Other (-5.79% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
COLL($1.24B) has a higher market cap than ESPR($496M). COLL YTD gains are higher at: -1.780 vs. ESPR (-44.091). COLL has higher annual earnings (EBITDA): 308M vs. ESPR (-150.11M). COLL has more cash in the bank: 311M vs. ESPR (82.2M). ESPR has less debt than COLL: ESPR (266M) vs COLL (674M). COLL has higher revenues than ESPR: COLL (567M) vs ESPR (116M).
COLLESPRCOLL / ESPR
Capitalization1.24B496M250%
EBITDA308M-150.11M-205%
Gain YTD-1.780-44.0914%
P/E Ratio30.17N/A-
Revenue567M116M489%
Total Cash311M82.2M378%
Total Debt674M266M253%
FUNDAMENTALS RATINGS
COLL vs ESPR: Fundamental Ratings
COLL
ESPR
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
58
Fair valued
35
Fair valued
PROFIT vs RISK RATING
1..100
42100
SMR RATING
1..100
3198
PRICE GROWTH RATING
1..100
7492
P/E GROWTH RATING
1..100
93100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ESPR's Valuation (35) in the Biotechnology industry is in the same range as COLL (58) in the Pharmaceuticals Other industry. This means that ESPR’s stock grew similarly to COLL’s over the last 12 months.

COLL's Profit vs Risk Rating (42) in the Pharmaceuticals Other industry is somewhat better than the same rating for ESPR (100) in the Biotechnology industry. This means that COLL’s stock grew somewhat faster than ESPR’s over the last 12 months.

COLL's SMR Rating (31) in the Pharmaceuticals Other industry is significantly better than the same rating for ESPR (98) in the Biotechnology industry. This means that COLL’s stock grew significantly faster than ESPR’s over the last 12 months.

COLL's Price Growth Rating (74) in the Pharmaceuticals Other industry is in the same range as ESPR (92) in the Biotechnology industry. This means that COLL’s stock grew similarly to ESPR’s over the last 12 months.

COLL's P/E Growth Rating (93) in the Pharmaceuticals Other industry is in the same range as ESPR (100) in the Biotechnology industry. This means that COLL’s stock grew similarly to ESPR’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
COLLESPR
RSI
ODDS (%)
N/A
Bullish Trend 4 days ago
80%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
82%
Bullish Trend 4 days ago
89%
Momentum
ODDS (%)
Bearish Trend 4 days ago
69%
Bearish Trend 4 days ago
87%
MACD
ODDS (%)
Bearish Trend 4 days ago
70%
Bearish Trend 4 days ago
86%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
67%
Bearish Trend 4 days ago
88%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
69%
Bearish Trend 4 days ago
86%
Advances
ODDS (%)
Bullish Trend 8 days ago
73%
Bullish Trend 15 days ago
84%
Declines
ODDS (%)
Bearish Trend 4 days ago
66%
Bearish Trend 4 days ago
89%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
74%
Bullish Trend 4 days ago
80%
Aroon
ODDS (%)
Bearish Trend 4 days ago
73%
Bearish Trend 4 days ago
90%
View a ticker or compare two or three
Ad is loading...
COLL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ESPR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RMBNX36.01-1.22
-3.28%
RMB Mendon Financial Services C
WAAEX33.35-1.39
-4.00%
Wasatch Small Cap Growth Investor
OISVX12.08-0.60
-4.73%
Optimum Small-Mid Cap Value Instl
RWGIX4.53-0.24
-5.03%
Wedgewood Institutional
STEYX12.51-0.84
-6.29%
AB International Strat Eqs Adv

ESPR and

Correlation & Price change

A.I.dvisor tells us that ESPR and ALKS have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ESPR and ALKS's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ESPR
1D Price
Change %
ESPR100%
-4.65%
ALKS - ESPR
30%
Poorly correlated
-5.05%
PTPI - ESPR
29%
Poorly correlated
-2.19%
ZOMDF - ESPR
26%
Poorly correlated
-9.57%
EVO - ESPR
26%
Poorly correlated
-4.97%
VTRS - ESPR
25%
Poorly correlated
-6.62%
More